Vertical Aerospace Ltd. current report, Q4 FY2023

Full document

Vertical Aerospace Ltd. Form 6-K Summary

Business context and reporting period

Vertical Aerospace Ltd., a United Kingdom-based electric vertical takeoff and landing aircraft developer, filed this Form 6-K for December 2023. The filing reports a New York Stock Exchange continued-listing deficiency notice received on November 28, 2023 and publicly announced on December 1, 2023.

Financial and operating metrics

  • The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating-financial metrics.
  • The filing concerns stock-exchange listing compliance rather than periodic financial results.

Material changes versus the prior comparable period

  • The company’s common stock fell below the NYSE minimum average closing-price requirement of $1.00 per share over a consecutive 30-trading-day period.
  • The filing does not identify a comparable prior-period financial change.

Guidance, outlook, risks, and unusual items

  • Vertical notified the NYSE that it intends to cure the deficiency and remain listed.
  • The company has a six-month cure period following receipt of the notice. It may regain compliance if, on the last trading day of any calendar month during that period, its closing share price is at least $1.00 and its 30-trading-day average closing price is at least $1.00.
  • The notice has no immediate effect on the listing; the shares are expected to remain listed during the cure period and the company does not anticipate an impact on ongoing operations.
  • Failure to regain compliance within the applicable period could create a risk to continued NYSE listing. The filing states that the company will consider available options, but does not specify those actions.
  • Forward-looking statements regarding regaining compliance, continued NYSE trading, and operational impact are subject to risks described in the company’s Form 20-F filed March 22, 2023 and subsequent SEC filings.

Important facts for investors to verify

  1. Whether the company achieved the required $1.00 closing-price and 30-trading-day average-price thresholds during the six-month cure period.
  2. Any subsequent NYSE decision regarding continued listing or delisting.
  3. Subsequent filings for the company’s cash position, financing needs, operating results, and other factors that may affect its ability to remain listed.
  4. The risk factors in the company’s Form 20-F and later SEC filings.